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Abstract
The increased prevalence of lifestyle diseases, such as the metabolic syndrome and type 2 diabetes mellitus (T2DM), calls for more knowledge on dietary
treatments targeting the specific metabolic pathways involved in these conditions. Several studies have shown a protein preload before a meal to be effective
in lowering the postprandial glycaemic response in healthy individuals and patients with T2DM. The aim of the present study was to assess the effect of a
marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose metabolism in healthy, middle-aged to elderly subjects. This
double-blind cross-over trial (n 41) included two study days with 4–7 d wash-out in between. The intervention consisted of 20 mg of MPH (or casein as
control) per kg body weight given before a breakfast meal. The primary outcome was postprandial response in glucose metabolism, measured by samples of
serum glucose, insulin and plasma glucagon-like peptide 1 (GLP-1) in 20 min intervals for 180 min. In a mixed-model regression analysis, no differences
were observed between MPH and control for postprandial glucose concentration (mean difference: −0·04 (95 % CI –0·17, 0·09) mmol/l; P= 0·573) or
GLP-1 concentration (mean difference between geometric means: 1·02 (95 % CI 0·99, 1·06) pmol/l; P = 0·250). The postprandial insulin concentration
was significantly lower after MPH compared with control (mean difference between geometric means: 1·067 (95 % CI 1·01, 1·13) mIU/l; P= 0·032). Our
findings demonstrate that a single dose of MPH before a breakfast meal reduces postprandial insulin secretion, without affecting blood glucose response or
GLP-1 levels, in healthy individuals. Further studies with repeated dosing and in target groups with abnormal glucose control are warranted.
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The proportion of the population with health problems related
to overweight and obesity is constantly increasing worldwide,
and this constitutes a great risk factor for several lifestyle
diseases such as insulin resistance, the metabolic syndrome
and type 2 diabetes mellitus (T2DM)(1). The ability of the
body to control postprandial glucose metabolism is decisive
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for health. Several dietary treatments for the prevention of
postprandial hyperglycaemia in both diabetic and non-diabetic
individuals have been suggested, but the necessary lifestyle and
diet changes are challenging, and continue to lack adherence(2).
There is a need for more knowledge on dietary treatments tar-
geting the specific metabolic pathways involved in overweight,
obesity, the metabolic syndrome and T2DM.
Diets relatively high in protein (18–30 % energy) have been
shown to be effective in the management of obesity due to
suppression of appetite(3), and are further suggested to reduce
postprandial blood glucose in both healthy individuals and
patients with impaired glucose metabolism(4). Several trend
diets have over the last decades included high-protein diets
to reduce weight and suppress insulin response(5,6), but the
long-term effects of high-protein diets are unknown(7,8).
Furthermore, several studies have shown a protein preload
before a meal to be effective in lowering the postprandial gly-
caemic response both in T2DM patients and healthy
subjects(9–13).
Due to limited access to high-quality protein in the world, it
is neither sustainable nor possible for the world’s population
to increase the proportion of protein in the diet. Thus, the
potential benefit of altering the source and quality of protein,
rather than increasing the amount, is of great interest. Marine
resources in excess should be evaluated as a possible high-
quality protein source for human consumption(14).
Previous studies in rats and human subjects have shown
that the intake of both fish proteins and marine protein hydro-
lysates (MPH), even in low doses, has a desirable effect on
insulin sensitivity and postprandial glucose(7,15–19), lipids in
serum and adipose tissue, bile acids, fatty acid composition
and growth, and possibly has antihypertensive and immune-
modulating effects(14,19–23). It is indicated that MPH may con-
tain marine bioactive compounds with potentially important
biological effects in humans, beyond the known effect of pro-
tein as a source of amino acids(24,25). The use of MPH as a
dietary supplement with similar or better health benefits than
a regular fish meal could be both cost-effective, environmen-
tally friendly and sustainable. A low dose of MPH is presumed
to be effective due to the content of bioactive peptides not
equally present in other protein sources.
Thus, the present study was designed to assess the effect of
a single, low dose of MPH before a meal on postprandial glu-
cose metabolism in healthy, middle-aged to elderly subjects.
Subjects and methods
Trial design
The study was a double-blind cross-over trial, including two
different study days, with a 4–7 d wash-out period in between.
The intervention implemented 20 mg of MPH per kg body
weight (test material) or control (casein). MPH or casein pow-
der (identical, both flavoured with lemon) was mixed with
water and taken before a standardised breakfast meal, in ran-
domised order. The primary outcome was postprandial
response in glucose metabolism, measured by venous samples
of serum glucose and insulin, and plasma glucagon-like
peptide 1 (GLP-1). The secondary outcome was adverse
events measured by symptom questionnaires.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human subjects were approved by the Regional
Committees for Medical and Health Research Ethics of
Central Norway (2017/1794). Written informed consent was
obtained from all subjects. The trial was registered at clinical-
trials.gov as NCT03669796.
Participants
Participants were recruited through advertisements on the
Internet and posters at Haukeland University Hospital and
Ålesund Hospital between October 2017 and February
2018. Potential participants were interviewed for general eligi-
bility and compliance with inclusion and exclusion criteria, and
suitable candidates were invited for a further screening visit. A
total of forty-one healthy and active individuals between 41
and 64 years old were included in the study (male, n 15; female,
n 26). The inclusion process is depicted in Fig. 1.
Inclusion criteria were aged 40–65 years old and BMI 20–
30 kg/m2. Exclusion criteria were fish allergy, pharmacologic-
ally treated diabetes mellitus, elevated blood pressure, chronic
diseases (that might affect the evaluation of the study end-
points) and acute infections. The participants were instructed
not to take any nutritional supplements containing n-3 fatty
acids for 1 week before the study start, and while participating
in the study.
Study protocol
The participants came to the research units on two different
occasions, with a 4–7 d wash-out period (Fig. 2). A clinical
examination by a physician, baseline biochemistry and mea-
sures of height, weight and blood pressure were done before
inclusion. The level of physical activity was assessed, and par-
ticipants were instructed not to change the level of physical
activity or diet composition during the study period.
A 3-d and 1-d prospective dietary record was filled out prior
to study days 1 and 2, respectively. On the day preceding each
study day, the participants were provided with a standardised
evening meal (oatmeal, rice or barley porridge) instructed to
be eaten before 20.30 hours, followed by fasting until the
next morning.
On study days, the participants came to the research units
between 08.00 and 09.00 hours. After blood samples, they
were served a drink with MPH or control, before a breakfast
meal was given. The first post-meal sample (0 min sample) was
taken 15 min after the breakfast was served.
The standardised breakfast meal consisted of two slices of
semi-coarse bread (50 % whole wheat, 80 g bread), 10 g mar-
garine, 20 g strawberry jam and 20 g white cheese, providing a
total of 355 kcal (1485 kJ), 41 g carbohydrate, 12·5 g protein
and 15 g fat. The drink provided on average 35·9 g carbohy-
drate and 145 kcal (607 kJ). Thus, including the drink, the
breakfast provided in total 500 kcal (2092 kJ) and 77 g carbo-























































































































Fig. 1. Flowchart depicting the inclusion process for the study evaluating the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on
postprandial glucose metabolism in healthy individuals aged 40–65 years. Participants were recruited through advertisements on the Internet and posters at
Haukeland University Hospital and Ålesund Hospital between October 2017 and February 2018.
Fig. 2. Study protocol for the evaluation of the effect of a marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose metabolism.























































































































breakfast was calculated to induce an adequate blood glucose
response. No coffee or tea was served, but water ad libitum.
The participants spent 4 h at the research units to allow for
repeated sampling of blood, at 20 min intervals until 180 min,
and monitoring of blood pressure.
Assessments
Assessment of the participants’ medical history, and measure-
ment of biochemical variables and safety parameters were con-
ducted at baseline.
During the study days, serum glucose and serum insulin
were measured at baseline and every 20 min for 2 h (120
min), with a final sample at 180 min. GLP-1 was measured
at baseline, time 0, 20, 40, 80 and 180 min. Blood pressure
was measured at baseline, after 40 min and after 180 min, as
a safety parameter.
Two questionnaires evaluating the participants’ self-
experienced symptoms were implemented to identify possible
adverse events during each study day. A visual analogue scale
was filled out six times during the study day, and a question-
naire validated for the evaluation of gastrointestinal symptoms
(Kane) was filled out at baseline and at the end of each study
day(26).
Estimation of nutritional intake
Calculations of energy and macronutrient intake were per-
formed using Kostholdsplanleggeren (Norwegian Food Safety
Authority and The Norwegian Directorate of Health, Oslo,
Norway)(27). The dietary records were used to evaluate the
composition of the baseline diet, to map the participants’ regu-
lar meal pattern and to compare the days prior to each study
day according to energy intake.
Test materials
The MPH and casein powder were delivered from the manu-
facturer (Firmenich Bjørge Biomarin AS) in neutral bottles
coded with participant number and study day. The bottles
were coded by a person not involved in the implementation
of the study and randomised according to a randomisation
list. Both study participants and all persons involved in
study conduction and analysis were blinded. The powder con-
tained 4 % protein (MPH raw material or casein) and 96 %
carbohydrate (maltodextrin). It was flavoured with lemon,
but otherwise neutral. It was not possible to identify the active
ingredient from the control, according to flavour or appear-
ance. Each participant was given 20 mg/kg body weight of
MPH or control. The drinks were made isonitrogenous, and
equal amounts of N in the form of casein were added to
the control drink. This was done to avoid any bias due to dif-
ference in N content between the MPH drink and the control
drink. The amount of protein (N x 6·25) in both drinks was on
average 1·6 g, constituting only a small fraction of the total
protein content of the standardised breakfast meal. Casein
was chosen as the control as it has previously shown to not
affect blood glucose or insulin sensitivity when compared
with proteins from cod and soya(28).
The MPH powder was made by Firmenich Bjørge Biomarin
AS by hydrolysing fish meat of Atlantic cod (Gadus morhua)
with Protamex® (Novozymes AS) followed by spray drying
of the soluble part of the enzyme digest. The MPH raw mater-
ial contained approximately 89 % protein by weight, <0·2 %
fat, 0 % carbohydrate, <3·0 % water, 10 % ash, 0·1 % NaCl,
1·7 % Na and 0·07 % chloride. Free amino acids accounted
for 4·77 % of total amino acids in the MPH, and the essential
amino acids:non-essential amino acids ratio was 0·70. Analysis
of the molecular weight distribution (Table 1) shows that
about 90 % of the peptides in the fish protein hydrolysate
have a molecular weight of 2000 Da or less (eighteen amino
acids or fewer), about 75 % of 1000 Da or less (ten amino
acids or fewer) while about 55 % have a molecular weight of
500 Da or less (five amino acids or fewer). Approximately
25 to 30 % of the peptides have a molecular weight less
than 200 Da, which represents small dipeptides and free
amino acids.
The casein contained approximately 88 % protein. The
amino acid composition of MPH and casein used as control
is presented in Table 2 (data obtained from Firmenich
Bjørge Biomarin AS).
The MPH was analysed at the Allergy Laboratory
(Haukeland University Hospital, Bergen, Norway) for allergen-
icity of the hydrolysate. Direct ELISA showed insignificant
reactivity of specific IgG and IgE to the hydrolysate in com-
parison with the reactivity against cod allergen. The allergen-
icity of the hydrolysate was so low that it was considered
unsignificant.
Analysis of blood samples
Baseline biochemistry was analysed according to standard
accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway) and the Department of Medical Biochemistry,
Ålesund Hospital (Ålesund, Norway).
Glucose and insulin were measured in serum according to
standard accredited methods at the Laboratory for Clinical
Biochemistry, Haukeland University Hospital (Bergen,
Norway). Serum was obtained by centrifugation of full
Table 1. Molecular weight distribution in the dry and solubilised marine








g/100 g in the
spray-dried powder
>10 000 – <0·1 <0·1
10 000–8000 88–71 0·1 0·1
8000–6000 70–53 0·6 0·5
6000–4000 52–36 2·1 1·9
4000–2000 35–18 7·2 6·3
2000–1000 17–10 14·8 13·0
1000–500 9–5 21·0 18·5
500–200 4–2 27·0 23·8























































































































blood at 2000 g at room temperature (20°C) for 10 min after
30–60 min of coagulation, using serum separator cloth activa-
tor tubes. Samples were aliquoted and stored frozen at −80°C
prior to analyses.
Plasma for GLP-1 determination was obtained by centrifu-
gation of EDTA full blood at 1800 g at −4°C for 10 min
within 20 min after blood sampling. To EDTA blood sam-
pling tubes were added 10 µl dipeptidyl peptidase-4 inhibitor
(DPP4-010; DRG Diagnostics) per ml EDTA blood prior
to sampling. GLP-1 plasma was aliquoted and stored frozen
at −80°C prior to analysis. The GLP-1 analyses were per-
formed using an ELISA kit from IBL International GmbH
(GLP-1 (7–36) active ELISA, reference RE53121).
Statistical analysis
Statistical analysis was performed using SPSS software (IBM
SPSS Statistics 24) and GraphPad Prism version 7.0
(GraphPad Software, Inc.). The Shapiro–Wilk test was used
to assess normal distribution. Mixed-model regression analysis
was conducted to evaluate the difference between MPH and
control. Non-normally distributed data were log-transformed
before analysis (insulin and GLP-1) and are presented as log
mean and back-transformed values. Paired t tests were used
to evaluate differences in nutrient intake between study days.
Two-way ANOVA with repeated measures was used to evalu-
ate differences between each time point. Graphical work was
conducted in GraphPad Prism. P values <0·05 were consid-
ered statistically significant.
The sample size was not calculated according to a power
analysis, due to lack of similar studies. Previous research
reporting on the effect of cod proteins in human subjects is
based on whole fish(16) or long-term use of fish protein sup-
plement(17,29); thus we did not find any data adequate for mak-
ing a basis for a power analysis representative for our design.
We decided to include forty participants (forty-one were
included), a number higher or similar to previously reported
in studies on cod protein(16,17,29).
Results
Participant characteristics
Overall, forty-one participants completed the trial, of whom
twenty-six were female. Mean age was 51 (SD 6) years, range
40–64 years. Mean BMI was 25·2 (SD 3) kg/m2. The recorded
mean energy intake (2084 (SD 504) kcal/d; 8719 (SD 2109) kJ/
d) was lower than the estimated energy need (2605 (SD 392)
kcal/d; 10899 (SD 1640) kJ/d) at baseline. The standardised
breakfast provided on the study days (500 kcal (2092 kJ)) cov-
ered 19·6 (SD 2·9) % of the participants’ total energy need. All
baseline biochemistry was within the current reference values.
Baseline characteristics are presented in Table 3.
Energy intake
Mean energy intake before study day 1 was 2030 (SD 550)
kcal/d (8494 (SD 2301) kJ/d). Mean intake before study day
2 was 2110 (SD 534) kcal (8828 (SD 2234) kJ/d). The energy
intake did not differ before the two study days (P = 0·201).
Postprandial measurements
Data at each time point are presented in Table 4. In a multi-
variable, repeated-measures linear mixed-effects regression
analysis, no differences were observed between MPH and con-
trol for glucose concentration (mean difference: −0·04 (95 %
CI –0·17, 0·09) mmol/l; P = 0·573). Mean fasting glucose
levels were numerically equal on both study days (5·1 (SD
0·4) mmol/l; P> 0·999). The peak in glucose concentration
Table 2. Amino acid and taurine composition of the marine protein
hydrolysate (MPH) from Atlantic cod (Gadus morhua) and the casein
control used in the present study
Amino acid




Aspartic acid 73·3 70·8
Asparagine 0·38 N/A


















* Branched-chained amino acids.
Table 3. Baseline characteristics of the forty-one participants included in
the study at Haukeland University Hospital and Ålesund Hospital between
October 2017 and February 2018*
(Mean values and standard deviations)
Characteristics Mean SD
Age (years) 51·0 6·0
BMI (kg/m2) 25·2 3·0
Systolic blood pressure (mmHg) 125 18
Diastolic blood pressure (mmHg) 78 11




Energy intake at baseline
kcal/d 2084 504
kJ/d 8719 2109
Carbohydrates (g/d) 226·7 68·5
Fat (g/d) 90·2 33·0
Protein (g/d) 92·9 23·6























































































































(Cmax) occurred 20 min after the meal for both MPH and
control and was numerically higher after MPH than after
the control drink (7·6 (SD 1·8) v. 7·4 (SD 1·5) mmol/l,
respectively; P = 0·997). The AUC was compared for the
nine glucose measurements. The AUC for the glucose concen-
tration was numerically equal between MPH (1078 (95 % CI
956·0, 1199·0) mmol/l × min) and control (1068 (95 % CI
944·8, 1190·0) mmol/l × min; P= 0·910).
The insulin concentration was significantly lower after MPH
compared with control (mean difference between geometric
means: 1·067 (95 % CI 1·01, 1·13) mIU/l; P = 0·032). Mean
fasting insulin levels were numerically higher before MPH
(6·4 (SD 5·8) mIU/l) than control (6·1 (SD 5·6) mIU/l; P >
0·999), but the insulin concentration peaked at a lower level
and at 20 min (69·6 (SD 52·7) mIU/l) after MPH whereas
the peak after the control drink was numerically higher and
occurred at 40 min (70·3 (SD 53·6) mIU/l). Women had sig-
nificantly lower insulin concentrations than men (mean differ-
ence between geometric means: 0·65 (95 % CI 0·45, 0·93)
mIU/l; P= 0·020), irrespective of intervention.
Table 4. Descriptive statistics* of the forty-one participants included in a study at Haukeland University Hospital and Ålesund Hospital between October
2017 and February 2018, evaluating the effect of marine protein hydrolysate (MPH) from Atlantic cod (Gadus morhua) on postprandial glucose
metabolism measured by serum glucose, insulin and glucagon-like peptide 1 (GLP-1) during exposure to MPH and control (casein) drinks
(Mean values and standard deviations)
MPH Control
Outcome Time Mean SD Log mean SD GM Mean SD Log mean SD GM
Glucose (mmol/l) Baseline 5·1 0·4 5·1 0·4
0 min 6·5 0·9 6·7 0·8
20 min 7·6 1·6 7·4 1·5
40 min 6·5 1·8 6·2 1·9
60 min 5·4 1·4 5·4 1·6
80 min 4·9 1·2 5·1 1·4
100 min 4·6 1·1 4·7 1·2
120 min 4·5 1·1 4·4 1·0
180 min 4·4 0·6 4·3 0·6
Insulin (mIU/l)† Baseline 6·4 5·8 1·6 0·7 4·9 6·1 5·6 1·5 0·7 4·6
0 min 33·8 34·3 3·2 0·9 23·8 34·9 30·4 3·3 0·7 27·5
20 min 69·6 52·7 4·0 0·6 57·1 68·0 47·7 4·0 0·6 56·3
40 min 64·8 51·1 4·0 0·6 52·0 70·3 53·6 4·0 0·7 55·1
60 min 57·2 46·2 3·8 0·6 45·7 61·4 49·0 3·9 0·6 49·3
80 min 42·9 33·9 3·6 0·6 35·0 51·7 47·3 3·7 0·7 39·7
100 min 36·4 39·3 3·3 0·7 26·9 40·8 42·0 3·4 0·7 31·3
120 min 28·6 31·3 3·0 0·8 20·6 30·1 37·9 3·0 0·8 21·1
180 min 12·2 17·7 2·1 0·9 8·0 12·4 15·1 2·2 0·8 8·7
GLP-1 (pmol/l) Baseline 6·2 9·5 1·5 0·6 4·4 6·2 9·5 1·5 0·6 4·4
0 min 8·1 9·1 1·9 0·6 6·5 8·8 9·9 1·9 0·6 7·0
20 min 8·0 9·4 1·9 0·5 6·4 7·9 9·3 1·8 0·6 6·2
40 min 7·2 9·1 1·7 0·6 5·6 7·3 9·0 1·7 0·6 5·7
80 min 6·9 10·3 1·6 0·6 5·0 7·0 9·6 1·6 0·6 5·2
180 min 6·8 10·1 1·6 0·7 4·8 6·5 0·8 1·6 0·6 4·8
GM, geometric mean (exp(log mean)).
* Log mean and GM are presented for non-normally distributed data (insulin and GLP-1). Glucose values are only presented as means and standard deviations due to approxi-
mately normal distribution.
† In a mixed-model linear regression analysis, the insulin levels were significantly lower after intake of MPH than control (P = 0·032).
Fig. 3. Metabolic response for serum glucose (a), serum insulin (b) and plasma glucagon-like peptide 1 (GLP-1) (c) concentrations after intake of a standardised
breakfast meal supplemented with a drink containing either marine protein hydrolysate (MPH; –○–) or control (casein; –●–). Results are presented for forty-one
healthy subjects. The study had a cross-over design and all subjects received both treatments in random order. Time point 0 min shows values measured right
























































































































No differences were observed between MPH and control
for GLP-1 concentration (mean difference between geometric
means: 1·02 (95 % CI 0·99, 1·06) pmol/l; P = 0·250). Mean
fasting GLP-1 levels were numerically equal on both study
days (6·2 (SD 9·4) pmol/l; P> 0·999). The peak occurred
right after intake of breakfast and test drink (0 min) and was
lower after MPH (8·1 (SD 9·1) pmol/l) than after control (8·8
(SD 9·9) pmol/l; P= 0·092). Results are presented in Fig. 3.
Adverse events
No adverse events were reported in the questionnaires or
otherwise observed.
Discussion
The study was designed to investigate the effect of a low dose
of MPH on postprandial glucose metabolism in healthy indivi-
duals. Our hypothesis was that supplementation with MPH
before a meal would beneficially affect the glucose response,
insulin and GLP-1 concentration compared with control. We
found that a single dose of 20 mg/kg body weight MPH pre-
meal supplement significantly lowered the postprandial insulin
response. Although we did not observe a reduction in post-
prandial blood glucose values and GLP-1 concentrations, we
postulate that our findings could indicate a potential beneficial
effect of MPH in individuals with reduced insulin sensitivity.
We hypothesise that MPH may enhance the insulin sensitivity
and affect other mechanisms involved in the blood glucose
uptake in peripheral tissue. The study participants were healthy
individuals with HbA1c levels within the normal range
(Table 2), thus one would expect normal blood glucose con-
centrations after a meal. We speculate that the effect of
MPH on postprandial glucose metabolism will be more dis-
tinct if further investigated in individuals with the metabolic
syndrome or T2DM.
The target of nutritional diabetic and pre-diabetic treatment
is to maintain a blood glucose level within the normal range.
Several studies have previously shown different sources of
protein preload before a meal to reduce the postprandial gly-
caemic response, both in healthy and diabetic individuals(9–13).
However, to our knowledge, data on the specific acute effect
of a fish protein hydrolysate supplement prior to a meal has
previously not been published.
Our finding is consistent with a previous study, showing
lower postprandial insulin C-peptide levels after a 7-d interven-
tion with cod(30). Furthermore, Ouellet et al.(16) have previously
demonstrated that a diet rich in cod improved insulin sensitiv-
ity in nineteen insulin-resistant individuals, when compared
with a diet rich in other animal protein sources. Also, it has
previously been demonstrated that cod protein-fed rats, in
comparison with casein-fed and soya-fed rats, are protected
against the development of insulin resistance and hypergly-
caemia induced by diets rich in fat and sucrose(28). This effect
was related to enhanced insulin-stimulated glucose uptake in
muscle cells, but not in adipose tissue. It is indicated that
amino acids derived from cod protein can increase the insulin-
stimulated glucose uptake in muscle cells by acting directly on
the glucose transport system(28). Investigations of the mechan-
isms promoting this positive effect of amino acids from cod
revealed that dietary cod protein restored insulin-induced acti-
vation of the phosphatidylinositol 3-kinase (PI3K)/protein
kinase B (Akt) pathway and improved translocation of
GLUT4 to the T-tubes in skeletal muscle cells(31). The glucose
transporter protein GLUT4 facilitates the uptake of glucose
into the cell when expressed at the cell surface, and it has
been proposed that a reduced translocation of GLUT4 to
the T-tubules leads to the development of insulin resist-
ance(31). It is proposed that the amino acids derived from
cod protein, in comparison with amino acids derived from
other protein sources, facilitate a unique pathway leading to
the increased expression of GLUT4 in the T-tubules and
enhanced insulin sensitivity(31).
The assumed beneficial effect of the amino acids derived
from cod can possibly be linked to the high concentration
of branched-chain amino acids (BCAA). It has previously
been demonstrated that serum levels of the BCAA leucine,
isoleucine and valine, as well as the amino acid lysine, is cor-
related with the insulin response(32). The effect has been linked
to the increase of hormones such as glucose-dependent insu-
linotropic polypeptide and GLP-1(33). Although it is estab-
lished that the BCAA leucine and isoleucine are the major
amino acids affecting blood glucose homeostasis, the effect
has not been observed when the amino acid concentration is
low(34). Interestingly, a significant stimulation of glucose
uptake in muscle cells by the PI3K/Akt pathway has been
observed when the BCAA were administered as dipeptides
in low concentrations(35). The MPH used in our trial have a
high concentration of BCAA (Table 1), and analysis of the
MPH used in the present study shows that about 10 % of
the di- and tripeptide fractions are present as leucine- and
isoleucine-containing peptides (data obtained from Firmenich
Bjørge Biomarin AS). Even though we did not observe an
increase of GLP-1 in relation to the intake of single, low
dose of MPH, our findings suggest that low concentrations
of MPH may increase insulin sensitivity. The casein used as
the control has higher concentrations of BCAA than the
MPH, but it differs from MPH regarding the fraction present
as di- or tripeptides. The casein used in the study is not a
hydrolysate, but present as whole protein, and does not con-
tain either peptides or free amino acids. Thus, we assume
that the BCAA-containing peptides present in MPH constitute
the unique, bioactive effect even when given in low concentra-
tions. We postulate that this is due to the rapid absorption of
intact bioactive leucine- and isoleucine-containing peptides via
peptide transporters in the upper jejunum and into the blood.
It has been shown that other sources of protein, such as casein
and whey, are necessary in much higher doses than MPH to
achieve significant alterations in the postprandial blood glucose
and insulin response(36,37).
One could argue that the control drink should be a true pla-
cebo and only contain glucose (maltodextrin), and no protein.
However, then it would be possible that the observed effect
could simply be due to differences in energy and N content.
To avoid this, the control drink contained casein, a protein























































































































sensitivity when given in low concentrations(28,38,39), to facili-
tate an isoenergetic and isonitrogenic placebo material. Both
the MPH and casein control drinks contained an equal amount
of protein, in total on average 1·6 g. This amount is negligible
compared with the total protein content of the breakfast meal
provided (12·5 g protein); thus the effect of MPH can be
attributed to the content of bioactive peptides and not the pro-
tein per se. In a clinical study comprising of 120, slightly over-
weight (BMI between 25 and 30 kg/m2) male and female
subjects, Nobile et al.(40) showed that oral doses of 1·4 and
2·8 g MPH from the codfish species blue whiting
(Micromesistius poutassou) taken daily for 90 d increased the
blood concentrations of both cholecystokinin and GLP-1.
Further, body weight composition was improved in favour
of reduced body fat mass. Daily doses higher than 1·4 g did
not give any further effects, demonstrating that MPH may
show bioactivity in humans when taken orally in the range
of 15–20 mg per kg body weight.
Previous studies have investigated the long-term effect of
fish protein intake in overweight, obese and/or diabetic indivi-
duals. Improvement in postprandial glucose regulation after
intake of 750 g fatty fish/week (for 8 weeks) in overweight/
obese adults has been demonstrated, but this effect was not
observed after intake of lean fish(15). Similar findings have
been reported in T2DM patients; Zhu et al.(41) demonstrated
that treatment with a fish protein hydrolysate improved glu-
cose and lipid metabolism, resulting in reduced fasting blood
glucose, insulin and HbA1c, compared with placebo.
Vikøren et al.(17) were the first to investigate the specific effect
of a fish protein supplement on postprandial blood glucose.
They found that low doses of a fish protein supplement
from cod (3 and 6 g) for 4 weeks resulted in lower levels of
fasting and postprandial glucose, including lower AUC for glu-
cose when compared with placebo, in thirty-four overweight
individuals. Another recent study found that supplementation
with cod protein for 8 weeks in forty-two overweight and
obese individuals had a beneficial effect on postprandial con-
centration of serum NEFA, but no effect was observed in
postprandial glucose or insulin concentration compared with
control(29). The most obvious difference when comparing
these studies with our study design is that they evaluated
the long-term effect of fish intake/fish protein supplement
in overweight and obese patients, while we were interested in
the acute effect of a fish protein hydrolysate after a meal in
healthy individuals.
There are elements with our design that may have affected
the outcome. Previous studies in human subjects have investi-
gated the effect of fish or fish protein supplementation over a
longer period of time. Thus, it will be interesting to investigate
a potential effect using different doses given over a period of
time. Furthermore, we investigated the effect of MPH in
healthy individuals, assumed to have a normal glucose
response. Our findings indicate that further research should
aim to include individuals with hyperglycaemia or abnormal
postprandial glucose control. The participants in this study
might have been too healthy to find a meaningful effect.
The significant lower insulin concentration observed after
intake of MPH could be important in patients with reduced
insulin sensitivity, thus should be further investigated in a
group of patients with the metabolic syndrome and/or
T2DM. It has to be considered that 1 week of wash-out for
the use of n-3 supplements before inclusion might not have
been enough; thus the short wash-out period may be regarded
as a limitation to our design.
Most previous studies have been performed in rodents, and
few data exist on the specific effect of MPH supplement in
human individuals. The effect of a low dose of MPH on the
postprandial glycaemic response has previously just been
hypothesised, and our study is the first to investigate this pos-
sible association. Thus, this double-blinded cross-over trial
investigating the effect of MPH supplement in human subjects
can be regarded valuable for future studies. We suggest that
the potential effect of MPH should be investigated over a
longer period, with higher doses in patients with impaired gly-
caemic response and reduced insulin sensitivity.
In conclusion, our findings demonstrated that a single dose
of MPH before a breakfast meal reduced postprandial insulin
concentration without affecting blood glucose response or
GLP-1 levels when compared with control (casein), in healthy,
middle-aged individuals. The mechanism for this effect is
unknown, and further studies are warranted in target groups
with abnormal glucose metabolism.
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